Plaque Psoriasis

These poster data presented at the Maui Derm Fall 2024 conference highlight changes in laboratory parameters for patients using the TYK2 inhibitor deucravacitinib.

Commercial and government-based sources on Google scored the highest in quality, while medical practices scored the lowest, for information on psoriasis.

In this analysis, the differences in adverse events resulting from JAKi among adults and children were evaluated.

These findings further endorse the need for health care quality improvements for veterans, given the rates of melanoma, skin cancer, and psoriasis.

In this review of August 2024, the editorial team highlighted major stories from the previous month related to FDA approvals and medications for atopic dermatitis and psoriasis.

These data suggest that there are a subset of individuals with complete skin clearance of their psoriasis who report residual effects of their condition.

Prefilled pens and fewer injections improve satisfaction in psoriasis patients with needle phobia, enhancing adherence and treatment effectiveness, a study finds.

Patients with psoriasis show greater H. pylori infection rates, but no link to psoriasis severity, suggesting further research is needed on this potential connection.

The Harris Poll evaluated patient preferences for psoriasis therapy, highlighting patient views through an online survey.

These data highlight the necessity of equality in access to treatment and to the future development of psychological intervention measures using country-specific differences.

This new analysis highlights the effect of this selective allosteric tyrosine kinase 2 inhibitor as an oral treatment for moderate-to-severe psoriasis.

Rates of adverse events leading to discontinuation were similar between populations of moderate-to-severe psoriasis and psoriatic arthritis.

These data on the efficacy of bimekizumab suggest positive therapeutic effects on nail, scalp, and genital lesions as well as quality of life.

This analysis suggests additional support may be required for tildrakizumab-associated adverse drug reactions, given these new insights.

These data suggest that physical activity interventions can lead to visible improvements in PASI scores after 20 weeks of implementation, as well as cardiometabolic improvements.

In this analysis, the biggest predictors of biologic initiation among individuals with diagnoses of psoriasis were evaluated.

These data suggest benefits to pregnant mothers with this condition following early biologic intervention, with treatment leading to rapid refractory pustular psoriasis remission.

These data point to differences between genders such as time to initiation of treatment, treatment choice, response to medication, adverse events, and adherence.

New study highlights racial disparities in psoriasis management, revealing non-Hispanic Black patients are twice as likely to receive a skin biopsy compared to White counterparts.

This analysis represents the first to indicate that extending guselkumab can lead to disease activity control among those with early complete skin clearance.

This interview segment involved a discussion with Gooderham regarding the implications of recent clinical trial findings for patients with scalp and body psoriasis.

In this interview, Gooderham highlights the ARRECTOR study findings which led to roflumilast foam’s supplemental new drug application to the FDA.

These data highlight gender differences related to dysmorphic concern and the prevalence of body dysmorphic disorder among those with various dermatologic disorders.

This supplemental new drug application for once-daily roflumilast foam follows positive results of the ARRECTOR phase 3 study.

These findings represent the first comprehensive research into the greater frequency of APS autoantibodies linked with treating psoriasis with TNF inhibitors.